A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Affordable Prescriptions for Patients Act of 2023
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.
Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Introduced in Senate
Read twice and referred to the Committee on the Judiciary.
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Message on Senate action sent to the House.
Received in the House.
Held at the desk.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line